A science journal pulled a controversial study about a bizarre life form against the authors' wishes
Scientists said they'd discovered bacteria that used the element arsenic — poisonous to life as we know it — to grow. If true, it expanded the possibilities for where life could exist on Earth — or on other worlds.
Several research groups failed to replicate the results, and argue it's not possible for a living thing to use something so toxic to make DNA and proteins. Some scientists have suggested the results of the original experiments may have been skewed by undetected contaminants.
On Thursday, the journal Science, which first published the research, retracted it, though not because of misconduct on the researchers' part.
'If the editors determine that a paper's reported experiments do not support its key conclusions, even if no fraud or manipulation occurred, a retraction is considered appropriate,' the journal's editor-in-chief Holden Thorp wrote in the statement announcing the retraction.
The researchers disagree with the journal's decision and stand by their data. It's reasonable to pull a paper for major errors or suspected misconduct — but debates and disagreements over the findings are part of the scientific process, said study co-author Ariel Anbar of Arizona State University.
'One doesn't retract a paper because the interpretation is controversial, or even because most disagree with the interpretation,' wrote Anbar in an email. 'At least, that hasn't been the case until now.'
Science has more frequently retracted papers for reasons beside fraud in recent years, said Thorp and Vada Vinson, Science's executive editor, wrote in a blog post.
NASA helped fund the original work. The space agency's science mission chief Nicky Fox said in a statement that NASA does not support the retraction and encourages Science to reconsider.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants
We recently compiled a list of Vaxcyte, Inc. stands second on our list among the best future stocks. Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from its Phase 2 study of VAX-24 in infants. The 24-valent vaccine candidate met all primary endpoints for safety, tolerability, and immunogenicity compared to Pfizer's Prevnar 20, with robust immune responses and no serious vaccine-related adverse events. Full data following the fourth booster dose is expected by year-end 2025. Building on this progress, Vaxcyte, Inc. (NASDAQ:PCVX) is advancing VAX-31, a 31-valent PCV targeting broader strain coverage, approximately 94% in U.S. children and 95% in adults. The final stage of its infant Phase 2 trial is underway, with topline results expected by mid-2026. Adult Phase 3 trials are set to begin in mid-2025. VAX-31 has received FDA Breakthrough Therapy designation for adults and investigational approvals for pediatric use, highlighting its potential to address significant unmet medical needs. The business also unveiled VAX-XL, its third-generation PCV candidate offering the broadest coverage yet, signaling continued innovation in its pipeline. To support commercialization, Vaxcyte, Inc. (NASDAQ:PCVX) is constructing a manufacturing facility at Lonza, expected to be operational by early 2026. Its strong cash reserves of approximately $3 billion provide the necessary funding for R&D and scale-up. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Strategically, the corporation is aligning clinical, regulatory, and manufacturing efforts to become a leader in the global pneumococcal vaccine market. The recent appointment of Dr. Olivier Brandicourt, former CEO of Sanofi, to its board reinforces this vision with deep commercial expertise. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
11 minutes ago
- Bloomberg
Brain Swelling on the Rise in Unvaccinated Kids With Influenza
An increasing number of US children infected with influenza are experiencing a rare and potentially fatal condition marked by swelling in the brain, researchers said. They identified 41 children around the age of five who developed the complication know as acute necrotizing encephalopathy over the past two flu seasons. Eleven died within days due to the building pressure in their brains, according to the report published Wednesday in the Journal of the American Medical Association.